JVM Bundle
Who Really Owns JVM Co., Ltd.?
Understanding a company's ownership structure is crucial, especially in dynamic sectors like healthcare automation. JVM Co., Ltd., a leader in medication dispensing systems, provides a compelling case study. Founded in 1977, the company has evolved significantly, making its ownership a key factor in its strategic direction and market position.
This analysis explores the JVM SWOT Analysis, detailing the evolution of JVM's ownership, from its roots to its current status. We'll uncover the influence of major shareholders, the composition of its board, and recent ownership trends that shape the company's future in the competitive landscape. The question of "Who owns JVM" and the implications for its stakeholders will be thoroughly examined, offering insights for investors and industry observers alike, including details about the Java Virtual Machine owner and JVM company history.
Who Founded JVM?
The company, initially named Hyupshin Medical Equipment, was established in June 1977. The early focus of the company was on the manufacture and marketing of its first medicine packager. This marked a crucial step in its evolution toward pharmacy automation.
Specific details about the founders' names, their backgrounds, and the initial equity distribution at the company's inception are not readily available in the provided search results. However, the company's early activities set the stage for its future growth and development in the healthcare technology sector.
The legal transfer of Hyupshin Medical Incorporated to HSMED occurred in July 1996. The company's registration as a venture company in July 1999 reflects a strategic move. The company's certification for EM Mark and CE for European specifications in December 1999 shows early efforts towards international market penetration.
Early Focus
The company's initial focus was on manufacturing and marketing medicine packagers. This was a pivotal move towards pharmacy automation.
Legal Transfer
Hyupshin Medical Incorporated was legally transferred to HSMED in July 1996. This marked a significant corporate restructuring.
Venture Company Status
The company was registered as a venture company in July 1999. This designation likely helped in securing funding and resources.
International Market Entry
JVM obtained EM Mark and CE certifications for European specifications in December 1999. This was a key step for international expansion.
Early Expansion
JVM began installing automated tablet dispensing and packaging systems (ATDPS) in hospitals and pharmacies in the U.S. and Canada in November 1999. This was a key step in international expansion.
Name Change
The company changed its name to JVM Co., Ltd. in April 2004. This name change likely reflected the company's evolution.
Ownership and Development
Understanding the Brief History of JVM reveals that the company's evolution involved strategic shifts in ownership and focus. While the exact details of the initial founders and early ownership structures are not available, the company's trajectory shows a clear focus on technological innovation and market expansion. The company's early efforts in obtaining certifications and expanding into international markets, such as the U.S. and Canada, highlight its early growth strategies. The company's name change in 2004, from Hyupshin Medical Equipment to JVM Co., Ltd., also marked a significant transition in its identity and market positioning. The company's journey from its inception to its current status reflects a commitment to advancing pharmacy automation and expanding its global footprint, which is a key factor in understanding the current JVM ownership and its future prospects.
- The company's initial focus was on medicine packagers.
- The company expanded into international markets.
- The company was registered as a venture company in 1999.
- The company changed its name to JVM Co., Ltd. in 2004.
JVM SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has JVM’s Ownership Changed Over Time?
The evolution of JVM ownership has seen significant changes since its initial public offering. Initially listed on the KOSDAQ in June 2006, the company has undergone ownership shifts, with key stakeholders emerging over time. As of June 11, 2025, the market capitalization of JVM stands at approximately $209 million, with a total of 11.5 million shares outstanding, reflecting the company's current valuation and ownership structure.
A pivotal moment occurred in 2016 when Hanmi Pharmaceuticals became the largest shareholder. This marked a substantial change in the company's ownership. As of June 2025, Hanmi Science Co., Ltd. holds a significant 39.19% stake, equating to 4,738,544 shares, making it the largest reported major shareholder. Other notable shareholders include the National Pension Service of Korea, holding 3.92% (473,939 shares), along with individual investors such as Yeon Shik Jeong and Sang-Wook Kim who hold minor stakes.
| Shareholder | Shares Held | Percentage |
|---|---|---|
| Hanmi Science Co., Ltd. | 4,738,544 | 39.19% |
| National Pension Service of Korea | 473,939 | 3.92% |
| Other Individuals | Varies | Minor |
In the context of global market penetration, JVM has strategically partnered with major distributors. This includes collaborations with McKesson in the US, which holds a 74% market share, and Dijkstra in Europe, with a 78% market share. These partnerships are crucial for expanding JVM's presence in international markets.
Key Ownership Highlights
The ownership of the Java Virtual Machine (JVM) has evolved, with Hanmi Science Co., Ltd. as the largest shareholder. Strategic partnerships with global distributors like McKesson and Dijkstra are key for market expansion.
- Hanmi Science Co., Ltd. holds 39.19% of shares.
- The National Pension Service of Korea holds 3.92%.
- Partnerships with major distributors support international market penetration.
- The market capitalization is around $209 million as of June 2025.
JVM PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on JVM’s Board?
The current leadership of JVM Co., Ltd. includes Dong-hwan Lee, who has served as CEO since January 23, 2011. Sang-Wook Kim is the Chief Technology/Science/R&D Officer. Understanding the JVM ownership and its leadership structure is crucial for anyone interested in the Java ecosystem. This includes knowing who owns JVM and the key decision-makers within the JVM company.
The board of directors at JVM Co., Ltd. comprises several members, including Gi-Seok Woo, Hee-Jin Kim, Jong-Oh Kim, Dong-Hwan Lee, and Sang-Jin Lee. Jong-Oh Kim and Hee-Jin Kim are part of the Audit Committee. Sang-Jin Lee has been an Independent Director/Board Member since March 23, 2023. While specific details on voting power and share structures aren't available in the provided data, corporate governance in South Korea typically requires disclosures on board diversity and compensation policies. For those interested in the Java Virtual Machine owner, understanding the board's composition offers insight into the company's direction.
| Board Member | Role | Notes |
|---|---|---|
| Dong-Hwan Lee | CEO | Since January 23, 2011 |
| Sang-Wook Kim | Chief Technology/Science/R&D Officer | |
| Gi-Seok Woo | Board Member | |
| Hee-Jin Kim | Board Member | Audit Committee Member |
| Jong-Oh Kim | Board Member | Audit Committee Member |
| Sang-Jin Lee | Independent Director/Board Member | Since March 23, 2023 |
As of March 31, 2024, the company confirmed the validity of all share possessions and stated it would review reducing shares if deemed inadequate. For more insights into the company's strategic direction and growth, you can explore the Growth Strategy of JVM.
Key Takeaways on JVM Ownership
Understanding the board of directors is crucial for grasping the JVM company's governance. The board includes key figures like the CEO and independent directors. Knowing who owns the rights to Java and the JVM helps in making informed decisions.
- Dong-hwan Lee has been CEO since 2011.
- Sang-Jin Lee is an Independent Director since March 2023.
- The company is reviewing its share structure.
- Corporate governance in South Korea requires disclosures on board practices.
JVM Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped JVM’s Ownership Landscape?
In the past few years, JVM Co., Ltd. has demonstrated consistent financial performance. For the year ending December 31, 2024, the company reported a net income of KRW 28,844.34 million, a rise from KRW 26,243.57 million the previous year. Revenue for 2024 reached KRW 159.43 billion, marking a 1.50% increase compared to 2023. Earnings saw a 9.91% increase. As of March 31, 2025, trailing 12-month revenue was $116 million, with a net income of $20.33 million.
As of June 5, 2025, insider ownership stands at 46.64%, while institutional ownership is at 11.20%. The company's stock price as of June 11, 2025, was $18.17. JVM's focus on investor relations, including an event on May 8, 2025, and the release of Q1 2025 business performance reports on April 29, 2025, reflects a commitment to transparency. The company’s total assets were KRW 284,799 million, and equity was KRW 202,336 million as of 2024.
| Metric | Value | Year |
|---|---|---|
| Net Income (KRW million) | 28,844.34 | 2024 |
| Revenue (KRW billion) | 159.43 | 2024 |
| Insider Ownership | 46.64% | June 5, 2025 |
| Stock Price (USD) | 18.17 | June 11, 2025 |
The financial stability and strategic initiatives of JVM Co., Ltd. indicate a solid ownership profile. Major shareholder Hanmi Science Co., Ltd., maintains a significant stake, contributing to the company's stability. To learn more about the company's growth strategy, check out the Growth Strategy of JVM.
JVM Ownership Trends
The company's ownership structure shows a mix of insider and institutional holdings. Recent financial results highlight consistent growth and profitability. The stock price reflects the market's valuation of the company.
Recent Financial Performance
Revenue and net income figures for 2024 show positive trends. The trailing 12-month data as of March 31, 2025, provides a snapshot of current performance. The company's investor relations activities enhance transparency.
Key Shareholders
Hanmi Science Co., Ltd. is a significant shareholder in JVM Co., Ltd. The ownership structure suggests a stable base. The company's focus on shareholder communication is evident.
Future Outlook
JVM's consistent profitability and market position suggest a stable outlook. The company's financial health, as indicated by its assets and equity, supports its stability. Ongoing investor relations efforts are key.
JVM Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of JVM Company?
- What is Competitive Landscape of JVM Company?
- What is Growth Strategy and Future Prospects of JVM Company?
- How Does JVM Company Work?
- What is Sales and Marketing Strategy of JVM Company?
- What is Brief History of JVM Company?
- What is Customer Demographics and Target Market of JVM Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.